MDGL MADRIGAL PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2023 - Phase 3 Clinical Trial Results Madrigal Pharmaceuticals announced the primary endpoint results from its Phase 3 clinical trial of resmetirom for the treatment of NASH, showing positive response rates for both doses in NASH resolution and fibrosis improvement.Get access to all SEC 8-K filings of the MADRIGAL PHARMACEUTICALS INC